XNASCGON
Market cap2.30bUSD
Jan 10, Last price
30.20USD
1D
-0.85%
1Q
-16.32%
IPO
-13.79%
Name
CG Oncology Inc
Chart & Performance
P/E
—
P/S
11,270.18
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
204k
+6.81%
Net income
-49m
L+37.14%
CFO
-46m
L+53.26%
Profile
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY |
|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | |
| Income | |||
Revenues | 204 6.81% | 191 -98.16% | |
Cost of revenue | 55,653 | 35,437 | |
Unusual Expense (Income) | |||
NOPBT | (55,449) | (35,246) | |
NOPBT Margin | |||
Operating Taxes | |||
Tax Rate | |||
NOPAT | (55,449) | (35,246) | |
Net income | (48,607) 37.14% | (35,443) 176.06% | |
Dividends | |||
Dividend yield | |||
Proceeds from repurchase of equity | 119,692 | ||
BB yield | |||
| Debt | |||
Debt current | 217 | 9,155 | |
Long-term debt | 705 | 7,141 | |
Deferred revenue | |||
Other long-term liabilities | 13 | 257 | |
Net debt | (186,752) | (127,185) | |
| Cash flow | |||
Cash from operating activities | (45,679) | (29,804) | |
CAPEX | (14) | ||
Cash from investing activities | (121,195) | (55,352) | |
Cash from financing activities | 86,997 | 119,692 | |
FCF | (55,434) | (33,712) | |
| Balance | |||
Cash | 187,674 | 143,481 | |
Long term investments | |||
Excess cash | 187,664 | 143,471 | |
Stockholders' equity | 177,948 | 121,535 | |
Invested Capital | 7,316 | 19,938 | |
ROIC | |||
ROCE | |||
| EV | |||
Common stock shares outstanding | 4,331 | 66,636 | |
Price | |||
Market cap | |||
EV | |||
EBITDA | (55,432) | (35,231) | |
EV/EBITDA | |||
Interest | 1,000 | ||
Interest/NOPBT | |||